A Phase 1/2 clinical trial is recruiting adults with late-onset Pompe disease to test Audentes Therapeutics‘ investigational gene therapy AT845, the company has announced. The trial (NCT04174105) will be conducted at clinical sites in the U.S., Germany, and the U.K. It aims to recruit up to…
AT845
Audentes Therapeutics plans to submit an investigational new drug (IND) application for its Pompe disease gene therapy AT845 this year. In a recent update, Audentes, a biotech company, discussed its portfolio of investigational gene therapies for rare diseases. “2018 was an outstanding year for Audentes,” Matthew…
Recent Posts
- Next-generation therapy may help babies with Pompe live longer, better
- I wonder about the questions my daughter hasn’t asked me yet
- TRPML1 activation may boost Pompe ERT effects in new cell study
- How a mother helps her daughter face Pompe disease treatment
- Muscle MRI may detect early changes in late-onset Pompe disease